| Ex Vivo Drug Sensitivity Testing and Mutation Profiling (NCT03860376) | Florida International University | 2019-02-21 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) (NCT03210714) | National Cancer Institute (NCI) | 2018-06-05 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) (NCT03233204) | National Cancer Institute (NCI) | 2017-09-14 |
| Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas (NCT01567046) | Children's Oncology Group | 2016-05-01 |
| Trabectedin and Irinotecan for Refractory Pediatric Sarcomas (NCT02509234) | Technical University of Munich | 2014-02-01 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (NCT01552434) | M.D. Anderson Cancer Center | 2012-10-16 |
| Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (NCT01614795) | National Cancer Institute (NCI) | 2012-06-18 |
| Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment (NCT00929903) | National Cancer Institute (NCI) | 2009-06-01 |
| Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors (NCT00831844) | National Cancer Institute (NCI) | 2009-01-01 |
| Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (NCT00720174) | National Cancer Institute (NCI) | 2008-06-01 |
| Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors (NCT00070109) | Children's Oncology Group | 2008-01-01 |
| Ixabepilone in Treating Young Patients With Refractory Solid Tumors (NCT00331643) | National Cancer Institute (NCI) | 2006-04-01 |
| Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas (NCT00101270) | National Cancer Institute (NCI) | 2005-03-01 |
| Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment (NCT00091182) | National Cancer Institute (NCI) | 2004-10-01 |
| Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors (NCT00093821) | National Cancer Institute (NCI) | 2004-09-01 |
| Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors (NCT00077454) | National Cancer Institute (NCI) | 2004-02-01 |
| Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood (NCT00030667) | National Cancer Institute (NCI) | 2002-05-01 |
| Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas (NCT00012181) | National Cancer Institute (NCI) | 2001-04-01 |
| Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma (NCT00919269) | Children's Oncology Group | 1999-03-15 |